Nifedipina Doc (Nifedipine)

Nifedipine, the active ingredient in Nifedipina Doc, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension, angina pectoris and Raynaud's phenomenon in adult patients.

GNH USA supplies Nifedipina Doc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is manufactured under GMP conditions. Our distribution network ensures timely delivery to healthcare facilities across multiple continents, including Europe, Asia, Africa and the Americas. The offering includes comprehensive regulatory documentation for import and compliance.

Nifedipine is used to manage conditions related to cardiovascular tone and peripheral blood flow.

Hypertension: reduces systemic blood pressure by causing arterial vasodilation. Angina pectoris: alleviates chest pain by improving coronary blood flow. Raynaud's phenomenon: diminishes vasospastic attacks in the extremities.

Nifedipine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dosing. - Flushing: transient warmth and redness of the skin, especially on the face. - Peripheral edema: swelling of the ankles or lower legs due to fluid accumulation.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that can cause dizziness or fainting. - Myocardial infarction: rare occurrence of heart attack, particularly in patients with pre‑existing coronary disease. - Allergic reactions: rash, itching, swelling, or anaphylaxis requiring immediate medical attention.

Before initiating therapy, clinicians should consider several safety measures.

Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. Cardiovascular status: avoid rapid dose escalation in patients with severe aortic stenosis or cardiogenic shock. Liver function: assess hepatic impairment, as metabolism may be reduced. Concomitant medications: review for CYP3A4 inhibitors or inducers that could alter drug levels. Pregnancy and lactation: use only if the potential benefit justifies the unknown risk to the fetus or infant. Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Nifedipine can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise plasma concentrations and increase toxicity risk. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): can lower effectiveness by accelerating metabolism. - Grapefruit juice: markedly elevates drug levels, potentially leading to severe hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: combined use may cause excessive lowering of blood pressure or heart rate. - Diuretics: additive antihypertensive effect; monitor electrolytes and renal function.